HR Execs on the Move

Forma Therapeutics

www.formatherapeutics.com

 
At FORMA, patients are our purpose. We are dedicated to delivering transformative medicines to patients with cancer and rare diseases. We are a fully-integrated, privately-held clinical stage biopharmaceutical company. A leader in metabolism, epigenetics and protein homeostasis focused on the discovery, development and commercialization of transformative medicines. Our proprietary R&D platform combines deep biology insight, chemistry expertise and clinical development capabilities to create differentiated drug candidates. We have delivered high-value clinical candidates to our partners and generated a broad proprietary portfolio of internal programs, ranging from pre-clinical to pivotal-stage, with the potential to provide profound patient benefit in hematologic, oncologic ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Elizabeth Spinney
 Executive Director, R&D Counsel Profile
Ken Bair
 SVP & Head of R&D Profile
Linea Aspesi
 Senior Vice President and Chief Human Resources Officer Profile
Mary Wadlinger
 Senior Vice President of Human Resources Profile
Mary Wadlinger
 Senior Vice President of Corporate Affairs and Chief Human Resources Officer Profile

Similar Companies

Quality Care Solutions Inc

Quality Care Solutions Inc is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Martin Imaging

Martin Imaging | Providing PET Imaging Solutions

Walgreen Co

Walgreen Co is a Deerfield, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Breas Medical

Breas was founded in 1991 in Gothenburg, Sweden and has become one of the global leaders in Home Mechanical Ventilation, Airway Clearance and Sleep therapy.

Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx`s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.